Inotiv, Inc. (NOTV) Financial Ratios
29 years of historical data (1997–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↓
15.88
↓-53% vs avg
5yr avg: 33.79
30Y Low4.1·High84.8
P/FCF
N/A
—
5yr avg: 207.83
30Y Low2.5·High26.3
P/B Ratio
↓
0.07
↓-94% vs avg
5yr avg: 1.18
30Y Low0.3·High6.8
ROE
↓
-44.8%
↓+12% vs avg
5yr avg: -50.7%
30Y Low-145%·High19%
Debt/EBITDA
↓
16.34
↓-8% vs avg
5yr avg: 17.72
30Y Low0.7·High34.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NOTV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inotiv, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $47M | $44M | $79M | $410M | $405M | $52M | $37M | $14M | $15M | $9M |
| Enterprise Value | $397M | $434M | $468M | $461M | $778M | $441M | $87M | $53M | $23M | $20M | $14M |
| P/E Ratio → | -0.14 | — | — | — | — | 37.01 | — | — | — | 17.60 | — |
| P/S Ratio | 0.02 | 0.09 | 0.09 | 0.14 | 0.75 | 4.52 | 0.86 | 0.85 | 0.54 | 0.63 | 0.46 |
| P/B Ratio | 0.07 | 0.35 | 0.26 | 0.29 | 1.14 | 3.86 | 6.83 | 3.48 | 1.30 | 1.82 | 1.25 |
| P/FCF | — | — | — | 207.83 | — | — | — | — | 6.51 | 17.29 | — |
| P/OCF | — | — | — | 2.83 | — | 37.73 | 40.21 | 20.98 | 4.05 | 12.44 | 8.80 |
P/E links to full P/E history page with 30-year chart
NOTV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Inotiv, Inc.'s enterprise value stands at 15.9x EBITDA, 53% below its 5-year average of 33.8x. The Healthcare sector median is 14.4x, placing the stock at a 10% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.85 | 0.95 | 0.81 | 1.42 | 4.92 | 1.44 | 1.22 | 0.87 | 0.81 | 0.70 |
| EV / EBITDA | 15.88 | 17.36 | — | — | 35.58 | 48.44 | 45.32 | 20.79 | 12.31 | 6.64 | — |
| EV / EBIT | — | — | — | — | — | 56.48 | — | — | 1150.72 | 15.37 | — |
| EV / FCF | — | — | — | 1213.48 | — | — | — | — | 10.61 | 22.10 | — |
NOTV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Inotiv, Inc. earns an operating margin of -6.0%. Operating margins have expanded from -14.2% to -6.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -44.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.7% | 12.7% | 22.7% | 28.9% | 28.7% | 33.7% | 30.2% | 29.6% | 30.8% | 31.8% | 21.6% |
| Operating Margin | -6.0% | -6.0% | -17.6% | -14.2% | -5.0% | 1.7% | -5.1% | -0.4% | 0.1% | 5.3% | -14.9% |
| Net Profit Margin | -13.4% | -13.4% | -22.1% | -18.4% | -61.6% | 12.2% | -7.7% | -1.8% | -0.7% | 3.6% | -15.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.8% | -44.8% | -49.4% | -33.5% | -145.1% | 19.3% | -51.2% | -7.3% | -2.0% | 11.1% | -35.5% |
| ROA | -8.8% | -8.8% | -13.2% | -11.6% | -52.5% | 5.7% | -9.0% | -2.2% | -0.8% | 4.3% | -14.4% |
| ROIC | -4.1% | -4.1% | -10.4% | -8.9% | -4.7% | 1.3% | -6.6% | -0.5% | 0.1% | 7.6% | -16.4% |
| ROCE | -7.0% | -7.0% | -12.5% | -10.7% | -5.2% | 1.0% | -11.3% | -0.7% | 0.1% | 12.6% | -27.4% |
NOTV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Inotiv, Inc. carries a Debt/EBITDA ratio of 16.3x, which is highly leveraged (397% above the sector average of 3.3x). Net debt stands at $387M ($409M total debt minus $22M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.01 | 3.01 | 2.61 | 1.56 | 1.07 | 1.66 | 4.79 | 1.55 | 0.89 | 0.56 | 0.72 |
| Debt / EBITDA | 16.34 | 16.34 | — | — | 17.67 | 19.15 | 18.99 | 6.49 | 5.17 | 1.59 | — |
| Net Debt / Equity | — | 2.85 | 2.48 | 1.42 | 1.02 | 0.34 | 4.61 | 1.50 | 0.82 | 0.50 | 0.67 |
| Net Debt / EBITDA | 15.48 | 15.48 | — | — | 16.82 | 3.88 | 18.26 | 6.25 | 4.76 | 1.44 | — |
| Debt / FCF | — | — | — | 1005.66 | — | — | — | — | 4.10 | 4.81 | — |
| Interest Coverage | -0.55 | -0.55 | -1.84 | -1.89 | -0.92 | 0.91 | -2.06 | -0.24 | 0.05 | 3.41 | -7.62 |
NOTV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.35x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.62x to 0.35x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.35 | 0.35 | 1.37 | 1.62 | 1.42 | 3.43 | 0.48 | 0.71 | 0.68 | 0.69 | 0.36 |
| Quick Ratio | 0.27 | 0.27 | 1.22 | 1.19 | 0.98 | 3.42 | 0.46 | 0.65 | 0.58 | 0.57 | 0.25 |
| Cash Ratio | 0.04 | 0.04 | 0.18 | 0.27 | 0.11 | 2.52 | 0.04 | 0.03 | 0.07 | 0.06 | 0.03 |
| Asset Turnover | — | 0.67 | 0.63 | 0.67 | 0.57 | 0.28 | 0.98 | 1.04 | 0.84 | 1.19 | 0.97 |
| Inventory Turnover | 9.79 | 9.79 | 20.89 | 7.25 | 5.47 | 98.75 | 60.33 | 28.03 | 15.42 | 18.12 | 11.02 |
| Days Sales Outstanding | — | 55.65 | 57.60 | 57.66 | 66.70 | 115.54 | 65.33 | 79.67 | 71.21 | 47.35 | 40.00 |
NOTV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inotiv, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 2.7% | — | — | — | 5.7% | — |
| FCF Yield | — | — | — | 0.5% | — | — | — | — | 15.4% | 5.8% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $32M | $26M | $26M | $24M | $14M | $11M | $10M | $9M | $9M | $8M |
Peer Comparison
Compare NOTV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NOTVYou | $10M | -0.1 | 15.9 | — | 12.7% | -6.0% | -44.8% | -4.1% | 16.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 PRA | $1B | 24.9 | 19.5 | — | 39.4% | 6.6% | 4.0% | 3.2% | 5.1 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See NOTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NOTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NOTV vs CRL
Side-by-side business, growth, and profitability comparison vs Charles River Laboratories International, Inc..
Start ComparisonNOTV — Frequently Asked Questions
Quick answers to the most common questions about buying NOTV stock.
What is Inotiv, Inc.'s P/E ratio?
Inotiv, Inc.'s current P/E ratio is -0.1x. The historical average is 27.2x.
What is Inotiv, Inc.'s EV/EBITDA?
Inotiv, Inc.'s current EV/EBITDA is 15.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.4x.
What is Inotiv, Inc.'s ROE?
Inotiv, Inc.'s return on equity (ROE) is -44.8%. The historical average is -14.8%.
Is NOTV stock overvalued?
Based on historical data, Inotiv, Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
What are Inotiv, Inc.'s profit margins?
Inotiv, Inc. has 12.7% gross margin and -6.0% operating margin.
How much debt does Inotiv, Inc. have?
Inotiv, Inc.'s Debt/EBITDA ratio is 16.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.